Get the Stockscreener App
2.31
3.99%
-0.07
Genelux Corp stock is currently priced at $2.31, with a 24-hour trading volume of 58,445.
It has seen a -3.99% decreased in the last 24 hours and a -36.17% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.40 pivot point. If it approaches the $2.28 support level, significant changes may occur.
Previous Close:
$2.38
Open:
$2.35
24h Volume:
58,445
Market Cap:
$80.61M
Revenue:
-
Net Income/Loss:
$-28.30M
P/E Ratio:
-3.4056
EPS:
-0.6783
Net Cash Flow:
$-21.30M
1W Performance:
+0.22%
1M Performance:
-36.17%
6M Performance:
-84.57%
1Y Performance:
-93.29%
1D Range:
$2.15
$2.35
52W Range:
$2.15
$40.98
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
858 483 0024
Address
2625 Townsgate Road, Suite 230, Westlake Village
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
Genelux Corp Stock (GNLX) Latest News
Woodward Diversified Capital LLC Boosts Stock Holdings in Genelux Co. (NASDAQ:GNLX) - MarketBeat
MarketBeat
Genelux executive acquires $6.5k in company stock and warrants - Investing.com India
Investing.com India
Genelux executive acquires $6.5k in company stock and warrants - Investing.com South Africa
Investing.com South Africa
Genelux executive acquires $6.5k in company stock and warrants By Investing.com - Investing.com Australia
Investing.com Australia
Genelux CEO Thomas Zindrick acquires $1.05m in company warrants - Investing.com India
Investing.com India
Genelux CEO Thomas Zindrick acquires $1.05m in company warrants - Investing.com South Africa
Investing.com South Africa
Genelux Corp Stock (GNLX) Financials Data
Genelux Corp (GNLX) Net Income 2024
GNLX net income (TTM) was -$28.30 million for the quarter ending December 31, 2023, a -443.44% decrease year-over-year.
Genelux Corp (GNLX) Cash Flow 2024
GNLX recorded a free cash flow (TTM) of -$21.30 million for the quarter ending December 31, 2023, a -488.40% decrease year-over-year.
Genelux Corp (GNLX) Earnings per Share 2024
GNLX earnings per share (TTM) was -$1.21 for the quarter ending December 31, 2023, a -567.77% decline year-over-year.
About Genelux Corp
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
0.66%
0.84%
Cap:
|
Volume (24h):